Joseph Gonzalez-Campoy
Endocrinology, Diabetes & Metabolism · Eagan, MNNPI 1720033640
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (37.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 53 manufacturers reported payments, led by Novo Nordisk at 38.9% of the total. Reporting peaked in 2023 at $2,888 and has fallen 88.1% since, to $342 in 2025.
Across 209 payments — averaging $40.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Corcept Therapeutics$2K
- AstraZeneca$1K
- Medtronic$475
- Amgen$184
- Abbott$145
- plus $2K from 47 others
Across 1 payment — averaging $6051.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$6K
What the payments were for
- Consulting fees$3,18038%
- Speaking & faculty fees$1,40017%
- Food & beverage$2,95135%
- Education$93711%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,400
- FARXIGA$930
- INTELLIS ADAPTIVESTIM$117
How this compares
$8,468 in reported general payments places this provider in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 293 | $426,930 |
| OzempicSemaglutide | 247 | $412,048 |
| MounjaroTirzepatide | 155 | $207,183 |
| TrulicityDulaglutide | 109 | $163,675 |
| FarxigaDapagliflozin Propanediol | 141 | $137,560 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $44,297 |
| InvokanaCanagliflozin | 40 | $37,609 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 156 | $32,695 |
| Repatha SureclickEvolocumab | 28 | $31,015 |
| KerendiaFinerenone | 37 | $28,748 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $21,966 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $21,246 |
| EliquisApixaban | 23 | $20,782 |
| HumalogInsulin Lispro | 65 | $19,748 |
| Novolog FlexpenInsulin Aspart | 36 | $18,820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Wegovy, Novolog | $3,293 | $434,109274 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $24 | $390,607329 claims |
| AstraZenecaFarxiga | $1,053 | $137,560141 claims |
| Johnson & JohnsonInvokana, Xarelto | $33 | $48,60752 claims |
| BayerKerendia | $63 | $28,74837 claims |
| MerckJanuvia | $100 | $10,09112 claims |
| AbbVieSynthroid | $96 | $3,40528 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Eagan
- Ayesha EbrahimEagan$3K
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Sidney JonesChaska$67K
- Maria CastroRochester$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.